drugset / Trial / NCT01894412
Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers
RandomizedCrossoverQuadruple-blindTreatment
Summary
The purpose of this study is to compare the safety and pharmacokinetic characteristics of HD203 liquid with those of etanercept (enbrel) prefilled injection after subcutaneous injection
Timeline
- Start
- 2013-07
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 25 mg | Subcutaneous |
| Subject | HD203 | Unknown | 25 mg | Subcutaneous |
Indications
No indication recorded.